Recently, AI pharmaceutical enterprisesAureka Biotechnologies, Inc.（Aureka Biotechnologies）Announced the completion of a $35 million Series A+ financing round. This round of financing was led bySequoia ChinaLeading investment,Matrix Partners, Boyuan Capital followed the investment, existing shareholdersFive Source Capital, Qiming Venture Partners, New Alliance Capital, and others continue to invest.This round of funding will be used to promote the self-developed innovative functional antibody design platform.AuraIDE™ Construction, enhance the development of base models and agent capabilities, improve high-throughput and high-content experimental platform facilities, and further打通 agents through key stages from project initiation, molecular design to transformation and implementation.Efficiency Increased by 50%, Five Pipelines Under ResearchAureka Biotechnologies, Inc. FoundedIn 2023, it is a platform-based biotechnology company focused on protein design and immunotherapy drug discovery.FounderDr. Weian Zhao is a tenured full professor at the University of California, Irvine, has been selected as one of the top 2% of scientists globally by Stanford, and was awarded the "35 Innovators Under 35" (TR35) by MIT Technology Review.He mentioned in the press release: "We are one of the few in the industry who can proveThe core pipeline is entirely designed by intelligent agents."Enterprises that can fully display the original data and prove that the improvement of biological foundation model capabilities directly corresponds to the enhancement of drug value."In standard target pointsIn terms of sub-design, Aureka's delivery efficiency is "about 50% higher" than traditional wet lab experiments; it can complete the process from project initiation to including somatic cells, mice, and pre-CMC within 9-12 months.Pre-toxicologyUpon full delivery of the commercial data package.It is reported that over the past two years, Aureka Biotechnologies, Inc. has reached BD or NewCo collaborations with multiple multinational pharmaceutical companies and investment institutions.Achieve Tens of Millions of Dollars in Revenue。
The self-developed pipeline focuses on three major disease areas: cardiometabolic, immunology, and central nervous system. Currently, there are more than ten pipelines under research, among which...One drug is about to enter the clinical stage, and two are entering the IND development stage.。
-Recommended Reading-
